Michel P Coleman
Overview
Explore the profile of Michel P Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
8428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forjaz G, Kohler B, Coleman M, Steliarova-Foucher E, Negoita S, Guidry Auvil J, et al.
J Natl Cancer Inst
. 2025 Jan;
PMID: 39799506
Childhood cancers are a heterogeneous group of rare diseases, accounting for less than 2% of all cancers diagnosed worldwide. Most countries, therefore, do not have enough cases to provide robust...
2.
da Silva B, Minicozzi P, Di Carlo V, Ssenyonga N, Khan Baloch F, Matz M, et al.
Cancer Epidemiol
. 2024 Dec;
94():102720.
PMID: 39689510
Background: Ovarian cancer survival in low- and middle-income countries is lower than in high-income countries, due to disparities in healthcare access and socioeconomic factors. This study aimed to describe trends...
3.
Allemani C, Azevedo E Silva G, Mathur P, Coleman M
Lancet
. 2024 Jul;
404(10450):320-322.
PMID: 38971176
No abstract available.
4.
Montel L, Coleman M, Murphy T, Balabanova D, Ciula R, Evans D, et al.
Int J Equity Health
. 2023 Jul;
22(1):142.
PMID: 37507731
Background: Women with breast cancer have different chances of surviving their disease, depending on where they live. Variations in survival may stem from unequal access to prompt diagnosis, treatment and...
5.
Matz M, Valkov M, Sekerija M, Luttman S, Caldarella A, Coleman M, et al.
Cancer Commun (Lond)
. 2023 Jul;
43(9):963-980.
PMID: 37488785
Background: Esophageal cancer survival is poor worldwide, though there is some variation. Differences in the distribution of anatomical sub-site and morphological sub-type may help explain international differences in survival for...
6.
Weir H, Bryant H, Turner D, Coleman M, Mariotto A, Spika D, et al.
J Registry Manag
. 2023 Jun;
49(1):23-33.
PMID: 37260622
Background: Population-based cancer survival provides insight into the effectiveness of health systems to care for all residents with cancer, including those in marginalized groups. Methods: Using CONCORD-2 data, we estimated...
7.
Matz M, Rhodes S, Van Tongeren M, Coleman M, Allemani C, Nafilyan V, et al.
J Epidemiol Community Health
. 2023 May;
77(8):481-484.
PMID: 37258216
Background: Excess mortality from all causes combined during the COVID-19 pandemic in England and Wales in 2020 was predominantly higher for essential workers. In 2021, the vaccination programme had begun,...
8.
Alkhalawi E, Allemani C, Al-Zahrani A, Coleman M
Gulf J Oncolog
. 2023 Feb;
1(41):17-22.
PMID: 36804155
Background: Population-based cancer survival is a key metric for the assessment of cancer control strategies. Accurate estimation of cancer survival requires complete follow-up data for all patients. Aim: To explore...
9.
Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, et al.
Lancet Oncol
. 2022 Nov;
24(1):e11-e56.
PMID: 36400101
Cancer research is a crucial pillar for countries to deliver more affordable, higher quality, and more equitable cancer care. Patients treated in research-active hospitals have better outcomes than patients who...
10.
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov M, et al.
Neuro Oncol
. 2022 Nov;
25(3):580-592.
PMID: 36355361
Background: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in...